)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Iconovo
Iconovo (ICO) investor relations material
Iconovo Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary23 Oct, 2026
Executive summary
Licensing discussions for ICOres and ICOpre advanced; securing at least one near-term agreement remains critical to commercial progress and financing.
Net sales rose sharply on development income, while operating losses narrowed and costs remained under tight control.
Financial highlights
Q3 net sales were TSEK 707 vs 7; 9M net sales increased 219% to TSEK 1,917 vs 601, exceeding FY2025 sales by 73%.
Q3 operating loss narrowed to TSEK 6,770 vs 8,828; 9M operating loss improved to TSEK 24,081 vs 30,173.
Net loss was TSEK 6,809 in Q3 vs 8,863 and TSEK 24,274 in 9M vs 30,396.
9M total costs declined 15% to TSEK 29,155; personnel costs fell 34% to TSEK 14,312, while raw-material costs rose to TSEK 4,213 from 1,933.
Outlook and guidance
Management aims to conclude at least one ICOres or ICOpre partner discussion in the near term; successful transactions are expected to materially support revenue and financing.
Based on budgets and business outlook, sufficient funding is expected for the next 12 months if anticipated near-term transactions are finalized successfully.
Oxytocin development for postpartum haemorrhage awaits a Gates Foundation funding decision; GLP-1 preclinical work was scheduled for evaluation later in autumn 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Iconovo
- Announced 36.6 MSEK rights issue, investor presentation, and focus on inhaled generics.ICO
Investor update - Improved financials and strategic partnerships set the stage for growth, pending key licensing deals.ICOQ2 2026
- Net sales grew 45% and losses narrowed, with financing secured and strategic partnerships advancing.ICOQ1 2026
- Declining sales and losses prompt capital raise and strategic shift toward partnerships and GLP-1 projects.ICOQ4 2025
- Strategic refocus and cost cuts in Q3 2025 position for growth in inhalers and semaglutide.ICOQ3 2025
- Restructuring and capital raise position the company for commercialization despite lower sales.ICOQ2 2025
- No Q3 revenue; key inhaler projects advanced, rights issue to fund next phase.ICOQ3 2024
- Strategic progress in inhaler IP, licensing, and obesity drug reformulation, with improved losses.ICOQ2 2024
- Iconovo pivots to commercialization, secures funding, and advances inhalable drug partnerships.ICOQ1 2025
Next Iconovo earnings date
Q4 202626 Feb, 2027
Iconovo
Next Iconovo earnings date
Q4 202626 Feb, 2027
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage